Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$193.98 USD
-2.44 (-1.24%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $193.81 -0.17 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASND 193.98 -2.44(-1.24%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Other News for ASND
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pharmaceuticals Inc
Is ASND likely to continue higher? 50 Day Moving Average Support shows up after sliding 0.64%
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Wedbush sees no threat to Ascendis' Yorvipath from competitor data